The top reasons drugs fail to be recommended for market access are:
1. Non-robust economics
2. Uncertain clinical benefit
3. Inappropriate trial design, comparator, or patient population
4. Increased drug costs
5. Safety concerns
All of these reasons signify the importance of evidenced-based strategy early in the development process and a development partner that keeps market access and reimbursement requirements front of mind.